FOB Savings Reduced To $6.4 Bil. In Revised Budget Outlook; Total Drug Savings, $100 Bil.
This article was originally published in The Pink Sheet Daily
Executive Summary
The administration's expectations for savings from follow-on biologics that can be applied to health care reform are clarified by the mid-year budget review and outlook released by OMB Aug. 25.
You may also be interested in...
Rx Contribution To Health Reform May Be $100 Bil. After All, Obama Suggests
What's another $20 billion among friends? Biopharma executives had to cringe when, during his July 22 press conference on health reform, President Obama discussed the industry's pledge to deliver $80 billion in savings to help fund the effort. Not only was there a rough edge to his description of the agreement, the President seemingly upped the amount industry may end up having to put on the table by 25 percent
Obama Pushing For “Better Prices” For Part D Drugs
White House finds additional $313 billion in savings – $75 billion from drugs – to pay for expanded health care reform.
More Rebates For More Coverage: Budget Seeks Medicaid Rx Rebate Of 22%
An increase in the Medicaid rebate amount to 22.1 percent and changes to how Medicaid rebates are collected account for almost $20 billion of the nearly $634 billion "health reform reserve fund" proposed in the White House's outline of the fiscal 2010 budget